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 I 
Abstract 
 
Rationale: There is currently little literature available that discusses the link between 
cancer and mental illness outside of the diagnosis of depression. 
Objective: The primary objective of this thesis project is to assess the impact of a cancer 
diagnosis on indicaors of an individual’s mental health, that is, the diagnoses of mental 
health disorders, the use of psychotropic drugs, and/or a referral to a mental health 
specialist after index diagnosis for cancer.  
Hypothesis:  It is hypothesized that there will be an increase in both the diagnosis of mental 
illness and the use of psychotropic drugs following a diagnosis of cancer.   
Method: The study was conducted using the Canadian Primary Care Sentinel Surveillance 
(CPCSSN) database. The electronic medical records of patients with incident cancer 
diagnoses, i.e. diagnosed within the past three years, were identified.  Those cases were 
then followed for a year, examined for mental health condition diagnoses and prescription 
of psychoactive drugs, and compared to a cancer-free, matched cohort.  
Results: It was found that oncology patients were twice as likely to have a subsequent 
mental illness indicator in the year after diagnosis (OR=2.05, 95% CI=1.68-2.50, p=0.001). 
The type of cancer did not appear to have an impact on whether or not the patient would 
experience a mental illness indicator (χ2=0.074, p=0.626). It did, however, impact the type 
of mental illness diagnosed (χ2=40.522, p<0.001) and the type of psychoactive drug 
prescribed (χ2=30.679, p<0.001).   
Conclusion: Implications of this study encourage the promotion of screening for mental 
illness in oncology patients.  
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Chapter 1  
1.1 Introduction  
 Two in five Canadians will be diagnosed with cancer in their lifetime and it is 
terminal in approximately 25% of those cases1. Due to the severity of the disease, many 
patients interpret a diagnosis of cancer as a death sentence2. The fear instilled by the 
diagnosis can lead to increased mental distress.  
Twenty-five percent of the general population will experience a mental illness in 
their lifetime3, 4. The prevalence is higher for those suffering physical ill health, especially 
chronic conditions, such as cancer3, 5. Mental disorders, such as depression and anxiety, 
have been shown to increase patient’s hospital stays and recovery time and reduce 
compliance and treatment efficiency6-8. Lengthened hospital stays increase the burden on 
Canada’s health care cost; however, easing the psychological distress can improve a 
patient’s quality of life (QOL) and offset medical costs9-11. 
There is currently little literature available that discusses the link between cancer 
and mental illness outside of the diagnosis of depression. This study aims to assess the 
effect of the first diagnosis of cancer on an individual’s mental health using the Canadian 
Primary Care Sentinel Surveillance Network (CPCSSN) database. 
 
1.2 Literature Review 
1.2.1 Quality of Life (QOL) and Life Satisfaction in Cancer Patients  
The World Health Organization (WHO)12 defines QOL as “a state of complete 
physical, mental, and social well-being”, not necessarily absence of disease. WHO12 further 
explains that an individual’s perception of their position in the community, their 
relationships, and their personal beliefs have a large impact on QOL.  
A number of factors influence the QOL of a patient diagnosed with cancer, such as 
acceptance of their diagnosis, body image, physical frailty and discomfort, ability for self-
care, dependence on others, and perceived loss of dignity13-17. A decreased QOL will have 
a negative impact on an individual’s mental health. While there is little research describing 
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the relationship, mental health disorders are common in cancer patients. This comorbidity 
harmfully affects QOL18.  In those diagnosed with terminal cancer, and thus having a short 
life expectancy, QOL becomes a crucial aspect of patient care.  
There are many features that encompass an individual’s quality of life (QOL), such 
as life satisfaction and feelings of hope. Standardized tools exist to measure QOL whereas 
others exist to assess its components, such as hopelessness. Life satisfaction is affected by 
a myriad of factors and is subjective, making it difficult to compare among people. Tools 
have been created to measure life satisfaction, such as The Satisfaction with Life (SWL) 
Scale19. This scale correlates with mental health and is predictive of future behaviours, 
such as suicide attempts. 
Hope is a key therapeutic factor that has been shown to affect cancer patients’ 
immune function, adjustment and coping skills, QOL, and overall feelings of well being20-
28. McMillian et al.29 defines hopelessness as a general negative outlook of the future and 
it is possibly the most important predictor of suicide. The Beck Hopelessness Scale (BHS) 
is a 20-item true-false response scale that serves as the standardized measure of 
hopelessness in patients29. Feelings of hopefulness are related to psychosocial elements of 
pain and therefore, pain can feel severe20, 30, 31. Chronically ill individuals with feelings of 
hopelessness experience depression and a desire to hasten death20.  
 
1.2.2 Prevalence of Mental Disorders in Cancer Patients 
Psychosocial problems are present in 25-50% of cancer patients and approximately 
25-33% of these patients develop depression, adjustment disorders, anxiety, or sleep 
disturbances9, 18, 32-43. Significant psychological distress is common across all stages of 
cancer16; however, uncertainty exists as to when the onset of mental disorders occurs in 
cancer patients. Some studies show that the prevalence of mental illness increases as death 
approaches15 while others confirm mental disorders present 6 months post diagnosis44-46. 
These studies differed in the type of cancer, cancer severity, and the type of mental health 
disorder analyzed as an outcome.  
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1.2.2.1 Adjustment Disorder and Major Depression 
The DSM-547 defines adjustment disorder as “the presence of emotional or 
behavioural symptoms in response to an identifiable stressor occurring within 3 months of 
the stressor”. The symptoms associated with adjustment disorder must be out of proportion 
of expected reactions and cause significant impairment in the individual’s functioning. 
There are several subtypes of adjustment disorder that correlate with a patient’s symptoms. 
For example, adjustment disorder with depressed mood may be difficult to isolate from 
depression. Adjustment disorder is situational, dependant on a life change or stressor. 
Major depressive disorder occurs when a patient has a depressed mood or a loss of interest 
or pleasure for a period of 2 or more weeks47. This mood is combined with several other 
symptoms, such as insomnia, diminished concentration, suicidal ideation, changes in 
appetite and weight, etc., that significantly impair a patient’s functioning.  
It is well established that depression significantly reduces a patient’s subjective 
health, may lead to poor treatment compliance, and may result in a worse outcome16, 17, 48-
50. Patients with depression tend to have a worsened adjustment to cancer. That is, they 
experience greater feelings of helplessness, hopelessness, fatalism, and they have a lower 
fighting spirit6. Clinical depression is reported to be the most frequent psychopathological 
complication occurring in oncology patients6, 51-54.  
There are variations in the reported prevalence of adjustment disorder and 
depression among cancer patients; it has been documented to range between 9-35% and 8-
26% respectively9, 16, 38, 39, 48, 55-77. Some studies have reported that the prevalence of 
adjustment disorder and depression in a population can reach as high as 50-65%9, 38, 39, 66, 
68, 78, 79. Not all depressed patients request treatment. One study by Okuyama et al.67 showed 
that only 28% of cancer patients that were considered depressed after nurse screening 
accepted psychiatric referral67, 80. 
 Some drugs used in cancer treatment, such as interferons, produce depression as a 
side effect. Patients that are prescribed these types of drugs are at an elevated risk of 
developing depression2, 81. 
Depressive symptoms that do not fit the Diagnostic and Statistical Manual of 
mental disorders (DSM) criteria for depression are regularly occurring in oncology 
patients6, 82, 83. Symptoms can range from typical reactions to their condition to extreme 
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anxiety or major depressive disorder (MDD)84, 85. Levels of depression are often 
underestimated by health care professionals18, 86, 87. 
Depression disorders are on a spectrum. It is possible for a patient’s depression to 
worsen over time and even persist after their cancer treatment84. Depressed patients may 
request euthanasia and are prone to a high risk of suicide84.  
Cancer has the potential to be life-threatening and anti-cancer treatments can be 
physically and psychological traumatic. The increased mental distress seen in these patients 
leads to an increased risk of developing a mental disorder and suicide ideation36, 72, 88. 
Oncology patients with depression are at an increased risk of suicide because of the strong 
correlations were seen between suicidal ideation and mental health, poor physical 
functioning, and significant pain72, 89-92. A study by Harwood93 reported that 62% of 
individuals who had committed suicide had a physical health condition, including cancer. 
 
1.2.2.2 Anxiety and Post-Traumatic Stress Disorder (PTSD) 
Anxiety disorders are highly prevalent in oncology patients and may exceed that of 
depression16, 94. Like depression, anxiety disorders have the potential to adversely affect an 
individual’s functional status16, 94. Anxiety disorders, most commonly generalized anxiety 
disorder (GAD), panic disorder, adjustment disorder with anxious mood, and PTSD, are 
diagnosed in 10-30% of oncology patients16, 94, 95. 
Generalized anxiety disorder causes excessive anxiety and worry, more days than 
not, for at least 6 months. Individuals with GAD find it difficult to control the worry and 
have accompanying symptoms such as fatigue, sleep disturbances, restlessness, etc. These 
symptoms cause significant impairment in the individual’s daily functioning47. PTSD is an 
anxiety disorder that develops after an exposure to traumatic life events which are out of 
the range of normal human experience. An individual reacts with psychological and 
physiological distress having symptoms lasting more than one month and significantly 
affecting their functioning47.  
Because of the severity of the disease, a diagnosis of cancer meets the DSM criteria 
of a traumatic event. Therefore, cancer patients are capable of experiencing full-PTSD or 
PTS-symptoms and 3-35% are diagnosed with the disorder38, 96-103. PTS symptoms tend to 
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be more frequent in cancers with an acute onset or a more fluctuating course when 
compared to a more stable or slowly progressing cancer104. 
 
1.2.2.3 Psychological Distress and Sleep Disturbances 
Cancer diagnoses and interventional procedures contribute to psychological 
distress and mood disturbances seen in patients. This disruption in the patient’s psyche can 
impede clear and rational thought36, 88, 105, 106. Patients with a strong desire to overcome 
their disease tend to have lower levels of psychological distress107. This phenomenon, 
known as the ‘fighting spirit’, can be measured using the mental adjustment to cancer 
(MAC) scale107, 108. 
Sleep disturbances are a common complaint in cancer patients. Twenty to seventy 
percent of women with breast cancer and 30-50% of men with prostate cancer reported 
difficulties sleeping at some point in their illness109-112. Oncology patients may be a 
population with an increased risk for sleep problems when compared to non-cancer 
controls113. 
It is possible that problems with sleep and anxiety disorders are clinically linked 
because sleep disturbances are included in 2 of 6 categories for anxiety in the DSM82, 114, 
115. Inadequate sleep may also lead to the development of other mood disorders and 
depressive symptoms105, 116. Some cases of severe insomnia were related to anxiety, 
depression, feelings of guilt, and significantly worse physical pain114, 117. 
 
1.2.3 Detection and Current Treatment Approaches 
Cancer patients and individuals with comorbid conditions were most likely to 
contact their general physician about mental, emotional, or nervous problems when 
compared to the general population33. Self-reported anxiety and depression scores can be 
used to predict the development of adjustment disorders and major depression in patients 
without clinical psychological distress at baseline. These symptoms should be controlled 
to prevent the development of psychological distress, even if it is at a subclinical level38. 
Kim et al.9 reported consultation rates from oncologists to consultation 
psychiatrists to be only 4%-10% among cancer patients and psychiatric assessment was 
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only given to 44.7% of patients with significant psychological distress9, 118-120. These 
findings are higher than a previous study that reported 28.2% of patients in need received 
necessary psychiatric treatment9, 80. Psychological distress is increasingly assessed in 
clinical trials but it is not yet a standard component of routine care32. Some oncology 
guidelines focus on distress management but other mental illnesses such as depression, 
anxiety, and sleep disorders may not be revealed in examinations32, 121.  
Mild to moderate symptoms of mental disorders such as anhedonia, guilt, and 
hopelessness are not easily recognized by oncologists6. Accurate diagnoses of depression 
depend on the training of the physician, the instruments used for evaluation, and the timing 
of evaluation relative to diagnosis and treatment32, 41, 68, 122-126. There are many factors that 
interfere with treatment for mental illness, but low mental literacy is a big patient-related 
barrier67. Some studies113, 127 show that only 30%-40% of the lay public can recognize 
depression accurately and many do not believe treatment is effective128.  
Psychological and pharmacological approaches have both been shown to be 
effective. However, combining both psychological and pharmacological interventions can 
maximize the desired outcome18, 38, 129, 130. De Fazio et al. 6 showed that antidepressant 
treatments reduced anxiety and depression in oncology patients that accepted treatment; 
however, anxiety and depression worsened in patients that refused pharmacotherapy.  
Mental health disorders are under-diagnosed and undertreated in oncology patients 
but assessing mental health continues to attract attention as researchers try to improve their 
QOL16. Effective diagnosis and treatment of psychiatric disorders has a positive effect on 
physical functioning and reduces morbidity and mortality3, 131, 132. Greater clarity of the 
nature of anxiety and depression in cancer patients would enhance our ability to recognize 
and treat it effectively16.  
 
1.2.4 Cancer Treatment in Canada 
 Primary care providers are typically the initial point of contact for patients and 
therefore, have a key role in cancer detection. This is reinforced by the fact that primary 
care providers are responsible to conduct routine screening for their patient population. 
Primary care providers function as a gatekeeper to the hospital and the specialists as well 
as an individual to provide continuity of care133. A cancer diagnosis, the initiation of 
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investigation into a possible cancer diagnosis, or the referral to a specialist is conducted by 
the primary care practitioner. The decision of cancer treatment is then managed by the 
specialists, typically medical and/or radiation oncologists. Finally, the primary care 
practitioner can continue caring for the patient with follow-up and managing other 
comorbidities.  
1.2.5 Literature Review Summary 
Based on the literature, there appears to be a strong relationship between cancer 
and mental health disorders. It remains uncertain as to the exact nature of the relationship. 
Previous research describes the relationship, but those studies varied on cancer type and 
severity, as well as the type of mental health disorder. Of the mental health disorders 
studied, it appears as though depression and anxiety are the most common psychiatric 
comorbidities in oncology patients. Primary care practitioners and oncologists should 
remain aware of this relationship and investigate for psychological distress in their 
patients.  
This study uses Canada-wide, primary care data from the CPCSSN database. The 
purpose is to compare data of individuals with and without a cancer diagnosis and 
analyze for subsequent mental health disorder indicators. The results from this analysis 
will add to the literature in this area as it looks at a generalized relationship between 
cancer and mental health. This generalization is beneficial as previous literature tends to 
focus on a specific subtype of either disease, cancer or mental health. There are 
limitations, however, with using this type of data and are identified in the discussion 
section.   
1.3 Study Objective:  
The primary objective of this thesis project is to assess the impact of a cancer 
diagnosis on indicators of an individual’s mental health. 
 
1.3.1 Research Question 
The study question is whether a diagnosis of cancer increases the likelihood of a 
subsequent diagnosis of a mental health condition. Specifically, in a cohort of patients, age 
20-65 years of age, will a first diagnosis of cancer result in an increased probability of 
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developing a mental health condition, (defined as an ICD9 code for a mental health 
condition being stated in the patient medical record, the use of psychotropic drugs, and/or 
a referral to a mental health specialist in the year after the cancer diagnosis) compared to a 
similar cohort who do not receive a diagnosis of cancer? 
 
1.3.2 Main Hypothesis 
The underlying hypothesis for this study is that patients who are diagnosed with 
cancer will be more likely to experience a mental health condition (as defined above) 
compared to individuals without a cancer diagnosis.  
 
1.3.2.1 Null Hypothesis 
Patients with cancer will not be more likely to be diagnosed with a mental health 
condition (as defined above) when compared to a control. 
 
1.3.2.2 Alternative Hypothesis 
Patients with cancer will be more likely to be experience a mental health condition 
(as defined above) when compared to a control.  
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Chapter 2  
2.1 Methods 
2.1.1 Sampling Frame/Data Source 
The Canadian Primary Care Sentinel Surveillance Network (CPCSSN) database 
was used in the study. CPCSSN contains de-identified health information on patients of 
participating primary care providers from across Canada134. It includes information of 
doctor-patient encounters, patient problem lists, prescriptions, laboratory data, 
investigations, etc. Each data item is coded and can be requested by researchers using such 
codes, e.g. ICD9 codes for diagnoses, DIN numbers for prescriptions, etc.   The network 
data abstraction process has passed ethics review at nine universities as well as the Health 
Canada Ethics Review Board.  Each regional network that contributes to the national 
CPCSSN database has gone through privacy impact assessments.  Case-definitions for the 
eight key chronic diseases being monitored have been developed and have undergone 
validity studies135-137. Data is collected from the EMRs of over 750 sentinels (i.e. primary 
health care providers) and stored on secure severs at Queen’s University134. The purpose 
of the CPCSSN database is to provide data for researchers and policy/decision makers on 
the prevalence and management of chronic disease in Canada134. 
The diagnosis of cancer will be included in CPCSSN if the primary care provider 
enters it in the EMR. This would be done at the time of diagnosis or during a subsequent 
follow-up appointment. Cancer is a medical condition that requires follow-up, and thus, a 
patient is likely to see their primary care provider throughout their cancer treatment. It is 
possible that this does not occur, in which case, the primary care provider would not enter 
the diagnosis in their EMR. This could be a source of non-identification of the dependent 
variable, however, the likelihood of this occurring is probably low. 
It was decided to use the CPCSSN database for this study due to its large size, 
including sentinels from across the country. It was selected for use, rather than hospital or 
cancer clinic data, as a control cohort was also needed for analysis. Ideally, oncology 
patients will be following-up with their primary care provider, and thus, included in the 
database. 
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2.1.2 Study Design 
This study used a retrospective (historical) cohort design. This study design occurs 
in present time and involves selecting participants based on existing status of a variable of 
interest. The outcome data, also measured in the past, can then be used for analysis137. The 
data for the exposed and unexposed groups and the data for the outcomes all existed in the 
database prior to the beginning of the study. The study examined the effect of a diagnosis 
of cancer on mental health. A study participant was determined to have developed a 
“mental health condition” during the year after a diagnosis of cancer if, in the CPCSSN 
database (patient medical records), there was, i) an ICD9 code for a mental health condition 
was present, ii) a DIN number for a prescription for psychotropic drugs, and/or iii) a referral 
to a mental health specialist). The exposure group (those with a diagnosis of cancer) was 
compared with a control group (those who did not receive a diagnosis of cancer) in terms 
of whether a mental condition occurred in the year after the cancer diagnosis. For the 
purpose of this study, the date of a diagnosis was considered to be the day in which the 
diagnosis was entered into the EMR. The data, coded in CPCSSN, could then be extracted 
from the database for a specified period of time, i.e. for a year from the diagnosis.  
 
2.1.3 Study Cohort 
The study population was obtained from the Canadian Primary Care Sentinel 
Surveillance Network (CPCSSN) database.  
Cohort Inclusion Criteria 
To be included in the study cohort, a person must  
1. be between the ages of 20 and 65 as of January 1, 2012 
2. not have had a prior diagnosis of cancer 
3. not have had a prior mental health condition (as defined in the Study Design 
section above) There were 92,305 individuals identified in the CPCSSN 
Database who met these inclusion criteria 
To clarify, each individual will not have had a diagnosis of cancer or mental health disorder 
listed in the EMR. To aid in reliability, the data for each individual is reviewed prior to 
January 1, 2012. This is done as a safeguard to avoid missing an existing cancer or mental 
health diagnosis.  
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Exposure Group 
This group contains people in the study cohort who receive a diagnosis of cancer 
(excluding brain and non-melanoma skin cancers) during the three-year period from 
January 1, 2012 to December 31, 2014. Non-melanoma skin cancers were excluded 
because once treated, they do not generally carry the same risk of death and the fear that 
most cancers carry. Brain tumours were excluded because the effect on mental health might 
be more directly caused by a physical impact on the brain, and thus, skew the results. 
 
Control Group 
This group contains people in the study cohort who did not receive a diagnosis of 
cancer during the three-year period from January 1, 2012 to December 31, 2014. The cohort 
was further defined from these unexposed individuals. For every exposed individual, 4 
unexposed individuals who are the same sex and who were born in the same year were 
randomly selected. 
 
2.1.4 Primary Outcome Variable 
The primary outcome examined is the occurrence of a mental health condition 
during the first year after cancer diagnosis.  A mental health condition was deemed to have 
occurred if:  
i) an ICD9 code was identified in the CPCSSN database indicating a mental health 
disorder diagnosis (ICD9 290-319). 
ii) there were one or more prescriptions for psychoactive drugs (antipsychotics, 
anxiolytics, hypnotics and sedatives, antidepressants, and psychostimulants), 
identified by DIN number. 
iii) and/or there was a referral made to a mental health specialist. 
 
2.1.5 Process of Establishing the Exposure Groups and Determining the Primary 
Outcome 
 The results of the process of establishing the exposed and control groups, and 
determining the primary outcome, are detailed in Figure 1 and Tables M1 and M2 at the 
end of this chapter. 
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2.1.6  Statistical Analyses 
The main aim of the analyses was to assess the risk of developing a mental health 
condition after acquiring a cancer diagnosis. The independent variable defines the cohort, 
that is, whether or not an individual has a diagnosis of cancer. The dependent variable is 
the development of a mental health condition. Univariate analysis describes the 
demographics of both the exposed and control groups was described using proportions and 
Mean (SD) depending on variable type. Bivariate analysis was conducted to compare 
outcomes between the two cohorts, assessing for statistical significance (using chi-squared 
analysis for categorical variables and t-test analysis for continuous variables). The relative 
risk and confidence intervals of the outcome given the exposure group was also 
determined. Missing data was identified and stated with the baseline characteristics of the 
cohort. Analysis was not conducted on a variable if it was missing for more than 20% of 
the cohort. If less than 20% was missing, the analysis was conducted and interpreted while 
considering the possible effects of the missing data.   
Multiple logistic regression analysis was conducted due to the dichotomous nature 
of the dependent variable. The regression serves to adjust for possible confounders based 
on the results of the univariate analysis. Variables were chosen as independent variables if 
they achieved a significance level of 0.2 or less under univariate analysis.  
There were limited number of variables available for use in the analysis due to 
limitations of the CPCSSN database and the matching process. Age and sex were used even 
though the groups were matched using those variables. This limited looking at differences 
by group (Exposed vs Control) of those variables but differences in development of mental 
health conditions could still be assessed.  There was not reliable data on variables which 
might be related to cancer, such as smoking status, occupation, and other 
SocioEconomicStatus (SES) variables. Furthermore, the breakdown of some variables had 
large differences, such as health care providers consisting of more than 95% Family 
Physicians. These variables were still used in the logistic regression as control variables. 
That is, to see if the relationship between mental health disorders and cancer persisted while 
controlling for other variables.  
Hence, the independent variables under logistic regression were cohort (whether 
they were in the cancer group or no cancer group); whether they were below or above the 
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median age (50 years) for the full study population; male or female; whether they lived in 
Western Canada or Eastern Canada; and whether their provider was a family doctor or 
some other provider designation. All analysis will be performed using SPSS Statistical 
Software 22.0139. 
 
2.1.7 Sample Size Adequacy 
The general population is expected to have a 25% prevalence of mental disorders3, 4. 
The sample size was calculated to detect a 10% difference between the control group and 
the exposure group. The sample size to compare two proportions can be calculated using 
the formula:  
n = (Zα/2+Zβ)2 * (p1(1-p1) + p2(1-p2)) / (p1-p2)2 
 
The study has an 80% power (Zβ) to detect a 10% difference with an alpha (α) value of 
0.05 if 2155 participants were enrolled. This population hold the control group at a 4:1 
ratio with the exposure group. Detecting a 10% difference between the control group and 
exposure group, assuming they have a 45% (p1 = control population proportion) and 55% 
(p2 = exposed population proportion) prevalence, respectively. The sample will have a 95% 
power with a significance level (α) value of 0.05 if 4019 participants were analysed at a 
4:1 ratio of control group to exposure group. This ratio of 4 control group participants to 1 
exposure group participant was implemented in order to increase the statistical power140. 
The final sample size is 6576 with an exposed group of 1316 and unexposed group of 5260. 
 
2.1.8 Ethical Considerations 
The provincial Health Research Ethics Board (HREB), established through the Health 
Research Ethics Authority, provided ethics approval (HREB File Number: 20170328). The 
level of intended data identification in the analysis was the location (province and urban/ 
rural) of participant. This was based on the first three digits of the postal code associated 
with each physician practice. A postal code with the second digit “0” is considered rural 
and any other digit is considered urban.  
The following safeguards were put in place to protect the identity of the patient’s 
information:  
 14 
- All members of the research team were briefed on their responsibility for privacy 
protection 
- As a general principle, no names, addresses, telephone numbers were recorded on 
paper or requested in data files 
- Any data-sharing agreements between the researcher and other researchers and/or 
institutions were signed prior to providing or obtaining access to data 
- All computer files pertaining to the study were password protected  
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Did Not 
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Mental Health 
Condition in the 
Year After the 
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in Their Matched 
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N=4825 
Individuals Meeting the Criteria for 
the Full Study Cohort on January 1, 
2010 
N=92305 
Exposed Group (Cases) 
Individuals Who Developed a 
Cancer Diagnoses (excluding brain 
tumours and non-melanoma skin 
cancers) between January 1, 2012 
to December 31, 2014 
N=1316 
Unexposed Group from Which the 
Control group was Pulled 
Individuals Who Did Not Develop a 
Cancer Diagnosis (excluding brain 
tumours and non-melanoma skin 
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Group Who Were the Same Sex 
and Were Born In The Same Year 
N=5260 
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Year After the 
Cancer Diagnosis 
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Year After the 
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Cancer Diagnosis 
in Their Matched 
Case 
N=435 
Figure 1: 
Establishing Exposed and Control Groups and Counting Primary 
Outcomes 
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Table M1. Cancers in the Exposed Group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Other is defined as cancers of lip, oral cavity, pharynx, liver, and pancreas. Also included are 
Kaposi’s sarcoma, neuroendocrine tumors, and neoplasms of unspecified behavior and 
other/unspecified sites. 
 
 
Table M2. Mental Health Conditions Identified in Exposed and Control groups 
Indicator of a Mental Health 
Condition Cohort Total 
N= 6576  Exposed 
N= 1316 
Unexposed 
N= 5260 
Mental 
Disorder 
Diagnosis 
Drug and Alcohol 
Use 15 (1.14%) 41 (0.78%) 56 (0.85%) 
Anxiety, Depression, 
Mood, & Stress-
Related  
125 (9.50%) 246 (4.67%) 371 (5.65%) 
Psychosis & Other 13 (0.99%) 39 (0.74%) 52 (0.79%)  
Psychoactive 
Drugs 
Antipsychotics 5 (0.38%) 18 (0.34%) 63 (4.8%) 
Anxiolytics 44 (3.34%) 69 (1.31%) 232 (17.8%) 
Hypnotics and 
Sedatives 37 (2.81%) 46 (0.87%) 120 (9.2%) 
Antidepressants 64 (4.86%) 184 (3.50%) 131 (10.1%) 
 Psychostimulants 2 (0.15%) 9 (0.17%) 195 (8.5%) 
Mental 
Health 
Referral 
Yes 6 (0.46%) 15 (0.29%) 21 (0.32%) 
No 1310(99.54%) 5245(99.71%) 6555 (99.68%) 
Cancer Type 
 
Only index diagnosis 
Total 
N=1303 
Respiratory & intrathoracic organs 66 (5.0%) 
Bone, connective tissue, skin, breast (male) 114 (8.7%) 
Genitourinary organs 152 (11.7%) 
Lymphatic & hematopoietic tissue 96 (7.4%) 
Carcinoma in situ 134 (10.3%) 
Colon 63 (4.8%) 
Breast (female) 232 (17.8%) 
Prostate 120 (9.2%) 
Neoplasms of uncertain behaviour 131 (10.1%) 
Other* 195 (8.5%) 
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Chapter 3  
3.1 Results 
 
Table 3.1 details the baseline characteristics of the two groups (Exposed and 
Control) described in Chapter 2: Methods. As expected, since the groups were matched on 
age and sex, there was no significant difference between the groups on these two variables. 
There was also no difference in the proportion of people in the two groups who lived in 
rural vs urban areas. Most lived in rural areas in both groups. 
There was a significant difference in the groups based on the proportion of patients 
seen at academic clinics vs community clinics, although overwhelmingly, the patients in 
both groups were seen in community clinics – 87.9% of the Exposed Group and 90.7% of 
the Control Groups.  
We had data on two western provinces (British Columbia and Alberta) and three 
eastern provinces (Ontario, Nova Scotia, and Newfoundland). Since there are more patients 
from the eastern provinces compared to the western provinces, it is not surprising that there 
were more Eastern Canadians in both groups (Exposed and Control). However, in the 
Exposed Group, 72.5% of patients were from the east and in the Control Group, 55.7% 
were from the east. This difference was statistically significant.  
The data on the patient’s main primary care provider is divided into Family 
Physician or Other.  Almost 99% of the patients had a Family Physician as their primary 
care provider. The remaining care providers were either nurse practitioners or listed as 
general practitioner rather than family physician; they are categorized as Other. It is 
difficult to interpret the analysis of data that has such large skewing. However, since there 
was a statistically significant difference it was used for analysis. There were more care 
providers categorized as Other in the Exposed (Cancer) Group. 
Table 3.2 is a contingency table comparing the primary outcome in the two groups 
(Exposed and Control). This table answers the main question in this study — “Are people 
with a new cancer diagnosis more likely to develop a mental health condition within a year 
after the cancer diagnosis compared to people who have not had a cancer diagnosis?”  The 
answer is yes. Patients who developed cancer were 2.08 times more likely to develop a 
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mental health condition within a year of the cancer diagnosis [OR 2.08 (CI: 1.74 – 2.49); 
P 0.001]. 
Table 3.3 looks at our other available variables in terms of their association with 
the primary outcome – mental health condition. Our available variables were: Sex, Age, 
Location of Residence(rural/urban), Practice Type (Academic/Community), Region of 
Canada (West/East), and Primary Care Provider (Family Physician/Other). People who 
were less than age 50 years old, lived in eastern Canada, and had a primary care provider 
that was not a Family Physician were significantly more likely to develop a mental health 
condition. Only those three variables, plus sex, were added into the multiple logistic 
regression along with the grouping variable (Exposed vs Control). The dependent variable 
was the primary outcome – development of a mental health condition indicator. The 
purpose of the regression analysis was to adjust the OR determined in the primary 
univariate analysis which showed an OR of 2.08 for the effect of cancer diagnosis on 
development of a mental health condition indicator(Table 3.4). Because we determined 
that other variables were also associated with the primary outcome we wanted to account 
for any effect these may have had on our results. Unfortunately, and as previously stated 
in the Method section, we did not have data on variables that are known to be associated 
with the development of mental illness, such as smoking status, education, occupation, and 
income. 
The adjusting of the OR based on the logistic regression decreased the OR slightly 
from 2.08 to 2.05 which does not affect the essence of our finding that the diagnosis of 
cancer doubles the likelihood of developing a mental health condition during the year after 
the cancer diagnosis. 
Other variables included in the logistic regression were age, where you live in 
Canada, and whether your primary care provider is a family doctor. Based on this analysis 
they all significantly affect the likelihood of developing a mental health condition (Table 
3.4). Individuals who were >50 years of age were 1.52 times more likely to develop a 
mental health condition. Eastern Canadians were 1.64 times more likely to develop a 
mental health condition than Western Canadians. Finally, patients who were treated by a 
family physician were 4.35 times less likely to develop a mental health condition than 
patients who were treated by another type of health care provider. The intention of this 
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analysis was to control for these variables when analyzing the primary outcome. As 
mentioned above, there are discrepancies in the distribution of these variables. For 
example, primary care provider broken into two groups, Family Physician (over 95%) and 
Other (less than 5%). Due to this limitation, the results of the logistic regression for these 
variables should be interpreted with caution.  
 
 
Table 3.1: Baseline characteristics of exposed (developed cancer) and unexposed (did not 
develop cancer) groups described in Chapter 2.  
 
Missing data: Sex – 44 cases; Age – 882 cases; Rural/Urban – 206 cases 
* Pearson Chi-Square (Continuity Correction) for categorical variables. ANOVA for continuous 
variables. 
 
  
 
Developed Cancer 
(Exposed) 
N= 1316 
Did not Develop Cancer 
(Unexposed) 
N=5260 
P Value* 
Sex 
Male 621 (47.7%) 2377 (45.5%) 
0.163 
Female 682 (52.3%) 2852 (54.5%) 
Age (Mean and SD) 1084 (49.01) 4610 (49.13) 0.712 
Age <50 years 536 (49.4) 2365 (51.3%) 0.272 50+ years 548 (50.6%) 2245 (48.7%) 
Location 
of 
Residence 
Urban 1053(20.6%) 1017 (20.0%) 
0.272 
Rural 241(81.4%) 4059 (80.0%) 
Practice 
Type 
Academic 
Centers 159 (12.1%) 490 (9.3%) 
0.003 Community 
Clinics 1157 (87.9%) 4770 (90.7%) 
Province 
BC 43 (3.3%) 154 (2.9%) 
0.001 
AB 319 (24.2%) 2175 (41.3%) 
ON 623 (47.3%) 1948 (37.0%) 
NS 166 (12.6%) 725 (13.8%) 
NL 165 (12.5%) 258 (4.9%) 
Region in 
Canada 
(West 
East) 
West 
(BC/AB) 362 (27.5%) 2329 (44.35) 0.001 East 
(ON/NS/NL) 954 (72.5%) 2831 (55.7%) 
Provider 
Family 
Physician 1252 (95.1%) 5239 (99.6%) 0.001 
Other 64 (4.9%) 21 (0.4%) 
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Table 3.2: Primary Outcome: Relationship Between Having A Diagnosis of Cancer and 
The Development of a Mental Health Condition Within the Next Year.  
 
 Developed A Mental Health Condition 
Did Not Develop A 
Mental Health Condition  
Exposed Group (Cancer 
Diagnosis) 
208 
(15.8%) 
1108 
(84.2%) 1316 
Control Group 
(No Cancer Diagnosis) 
435 
(8.3%) 
4825 
(91.7%) 5260 
 643 5933 6576 
OR 2.08 (CI: 1.74 – 2.49); P 0.001 
Interpretation: Patients who developed cancer were 2.08 times more likely to develop a mental health condition 
within a year of the cancer diagnosis. 
 
 
 
 
 
Table 3.3. Univariate Analysis of the Relationship Between Other Available Variables 
and the Development of a Mental Health Condition.  
 
 
 
Developed a Mental Health 
Condition OR (95% CI) 
P Value* Yes No 
Sex 
Male 362 (10.2%) 3172 (89.8%) 1.12 (0.95 – 1.32) 
0.187 Female 277 (9.2%) 2721 (90.8%) 
Age (Mean and SD) 47.34 (10.17) 49.29 (9.50) P=0.001 
Age 
(Dichotomized) 
<50 years 308 (10.6%) 2593 (89.4%) 1.38 (1.15 – 1.65) 
0.001 50 + years 222 (7.9%) 2571 (92.1%) 
Location of 
Residence 
Urban 507 (9.9%) 4605 (90.1%) 1.03 (0.83 – 1.26) 
0.833 Rural 122 (9.7%) 1136 (90.3%) 
Practice Type 
Academic 
Centers 65 (10.0%) 584 (90.0%) 1.03 (0.78 – 1.35) 
0.786 Community 
Clinics 578 (9.8%) 5349 (90.2%) 
Region in 
Canada (West 
East) 
West 
(BC/AB) 203 (7.5%) 2488 (92.5%) 0.64 (0.54 – 0.76) 
0.001 East 
(ON/NS/NL) 440 (11.3%) 3445 (88.7%) 
Primary Care 
Provider 
Family 
Physician 625 (9.6%) 5866 (90.4%) 0.39 (0.23 – 0.67) 
0.001 Other 18 (21.2%) 67 (78.8%) 
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Table 3.4. Logistic Regression of Variables Associated With the Development of a 
Mental Health Condition During the Follow-Up Period. 
Variables B/SE Odds Ratio Exp(B) 
Lower 
limit of 
95% CI 
Upper limit 
of 95% CI P Value 
Group 
 (Exposed vs Control) 
.717 
.102 2.05 1.68 2.50 0.001 
Age 0.420 0.097 1.52 1.26 1.84 0.001 
Sex .082 .095 1.09 0.90 1.30 0.388 
Region of Canada 
(East/West) 
.493 
.101 1.64 1.33 2.00 0.001 
Provider (Family 
Physician or Other) 
1.48 
.588 4.35 1.39 14.3 0.012 
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Chapter 4 
4.1 Discussion 
In this thesis project, it was hypothesized that patients who are diagnosed with 
cancer will experience more mental health conditions than individuals without a cancer 
diagnosis. It was found that those exposed to a diagnosis of cancer are twice as likely to 
develop a mental health condition within the first year of diagnosis compared to those 
without a cancer diagnosis. A mental health condition was assumed to have occurred if the 
patient was given a diagnosis on the EMR, prescribed psychoactive drugs, or given a 
mental health referral. 
A recently published article141 supports this finding as their study determined that 
depression affects up to 20%, and anxiety 10%, of patients with cancer. This compares to 
the general population rates of 5% and 7%, respectively. McDaniel’s142 results suggested 
that the prevalence of depression was substantially higher with the severity of the medical 
illness. A study published by Pitman et al141, however, found that there was no difference 
in prevalence of depression between oncology patients receiving end-of-life care when 
compared to oncology patients actively living with the disease. A Swedish study143 focused 
solely on men with prostate cancer. It found that the use psychotropic drugs for mood 
disorders was increased in terminal disease, indicating higher levels of psychological 
distress. Lycken143 suggested early identification of mental illness and improved 
counselling may help reduce the amplified distress seen in terminal patients. 
Approximately 15% of individuals diagnosed with cancer have a concurrent diagnosis of 
major depression. If dysthymia and minor depression is considered, this statistic rises to 
20%143. Exact numbers are difficult to determine because of the magnitude of influencing 
factors, i.e. stage of cancer, type of anticancer treatment, and screening and diagnostic 
tools143.  
Breitbart144 identified risk factors for developing a mental illness in oncology 
patients for early recognition and effective treatment of psychiatric comorbidities. He 
also found that depression, anxiety, and delirium were common mental illness 
experienced by many oncology patients145. Like McDaniel’s142 study, mental illness was 
correlated with advanced disease and aggressive anticancer treatment, ranging from 25%-
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77%. Breitbart144 concluded that additional risk factors for developing a mental disorder 
included uncontrolled symptoms, functional limitations, lack of social support, and a past 
psychiatric history. 
Desplenter et al.145 conducted a study titled Incidence and drug treatment of 
emotional distress after cancer diagnosis: A matched primary care case–control 
study.  They found that cancer patients were more likely to experience more emotional 
distress when compared to controls (15.6% vs 1.4%). This patient population was also 
found to be on a higher volume and duration of psychoactive drugs145. It is thought that 
cancer increases an individual’s vulnerability to developing depression in many ways. That 
is, the reaction to a diagnosis of cancer and the deterioration of health are both considered 
risk factors146. Anticancer treatments, including chemotherapy and corticosteroids and 
surgical treatment, pathological and medically-induced alterations to the patient’s 
physiology, and chronic pain pose additional risk for developing a mental illness, such as 
depression141,146. Furthermore, the study conducted by Pitman et al.141 concluded that some 
cancers (e.g. pancreatic and lung cancers) release chemicals that are thought to cause 
depression. 
Identifying oncology patients who have psychiatric comorbidities is key in order to 
assess and treat the patient holistically. These mental illnesses are known to cause a 
decreased quality of life, lower compliance with anti-cancer treatment, prolonged 
hospitalization, higher suicide risk, and greater psychological burden on caregivers146. In 
addition to these negative effects caused by psychiatric illness, depression is considered an 
independent risk factor for mortality in cancer patients146. In patients with depressive 
symptoms or a diagnosis of major depressive disorder, there is a greater mortality rate 
among cancer patients of 26% and 39%, respectively146. 
According to our results, people whose primary care provider was a family 
physician were less likely to develop a mental health condition. Another study, “Improving 
the detection and management of depression in primary care”147, determined that primary 
care and non-specialist practitioners may not be using current guidelines for diagnosis and 
treatment of depression. Use of simple questionnaires designed to measure depression 
and/or quality of life has not shown to impact recognition, management, or outcome of 
depression in non-specialist situations. Another perspective would be that patients of 
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family physicians may result in fewer mental health conditions because of the care 
received. Perhaps the patients are feeling more supported by their family physician and are 
not developing a mental illness indicator. It is important to remember that other healthcare 
providers are able to offer counselling for a patient’s mental health. Therefore, patients 
could be benefiting from the support of counsellors, psychologists, social workers, etc. 
These patients may not be followed by their primary care practitioner for this issue, and 
thus, appear to not have a mental health disorder.  
A Canadian study by Sunderland and Findlay148 assessed rates of unmet mental 
health care needs in individuals with mental illness. This becomes particularly concerning 
because, in 2012, approximately 10% of Canadians have a mental health condition, and 
these rates are estimated to increase. This study further evaluated the mental health care 
need in a 1-year span. Of their study population, 21% had their need partially met and 12% 
had unmet needs. Sunderland and Findlay148 identified distress as a predictor of mental 
health care need, which arguably could include presence of a physical illness. This is 
further supported by Statistics Canada157 who found that a chronic condition can precipitate 
a mood, anxiety, and substance use disorders. In order to provide holistic medical care to 
oncology patients and address these needs, the primary practitioner should collaborate with 
mental health specialists151.  
Although it was not reported, our analysis indicated that there was no significant 
difference found between cancer type and the presence of a mental health condition 
indicator. Contrary to this, Lichtenthal et al.151 concluded that 10.8% of deceased oncology 
patients had met the criteria for at least one of the following diagnoses: MDD, GAD, PD, 
or PTSD. The prevalence of these was highest in patients who were diagnosed with lung, 
colon, pancreatic, and breast cancer. Furthermore, a meta-analysis focusing on depression 
in oncology patients152, found differences in rates of depression differed in patients based 
on cancer type. That meta-analysis152 found cancers of the digestive tract, brain, and female 
genitalia, along with hematological malignancies, to have highest rates of depression. 
Definitive conclusions cannot be made due to small sample sizes, limited number of 
studies, and variation within cancer type.  
Again, although not reported in the results section, we found significant differences 
noted between the presence of a cancer diagnosis and the type of mental disorder diagnosis 
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experienced. This was also the case for the presence of a cancer diagnosis and the type of 
psychoactive drug prescribed. Anxiety, depression, mood, and stress-related disorders 
were found to be the most common category of mental health disorders diagnosed. 
Furthermore, this study determined that antidepressants were most the frequently 
prescribed psychoactive drug in the exposed cohort while anxiolytics were most frequently 
prescribed overall. A study by Derogatis et al.153 conducted in 1979 found that 51% of 
oncology patients were using psychoactive medications. Of these, 48% were hypnotics, 
26% were anti-psychotics, 25% were anti-anxiety agents, and 1% were antidepressants. 
Years later, a Jaeger154 conducted a study in 1985 that stated 61.3% of patients had 
psychotropic drug prescriptions. The breakdown of those being 55.8% hypnotics and 10% 
antidepressants. Both Derogatis et al.153 and Jaeger154 reported hypnotics as being the 
highest prescribed psychoactive drug and antidepressants as the lowest. This study found 
that antidepressants were prescribed to oncology patients more frequently than 
sedatives/hypnotics (4.86% vs 2.81%). It is thought that this change in prescription 
frequency is due to the advancements made in psychoactive drugs. The first 
antidepressants, monoamine oxidase inhibitors and tricyclic antidepressants, had 
unpleasant side effects and issues with safety and toxicity. Progress has been made with 
the development of selective serotonin reuptake inhibitors and serotonin and 
norepinephrine reuptake inhibitors. These medications are successful in treating depression 
with fewer unwanted side effects155.  
4.2 Study Limitation 
CPCSSN data has certain limitations. With the increased incorporation of 
technology in medical practice, paper charts are being replaced for EMRs. Not all 
physicians are embracing this change which results in a fraction of Canadian practitioners 
using EMRs and only a portion of those choosing to participate with CPCSSN. A study 
published in 2015 estimated EMR use in 62% of practitioners in 2013. They reported being 
limited as they conducted a survey to a small percentage of Canadian physicians156. 
However, CPCSSN does have data on about 1.5 Million patients from 750 physician 
practices and some work has been done on the representativeness of the data157. Due to the 
fact that CPCSSN extracts data from electronic medical records (EMR), there are 
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differences among patients that is healthcare provider dependent. The EMRs are used for 
clinical care and therefore, the data that researchers find useful are not always reported, 
such as SES variables. Depending on the patient and provider, the documentation may not 
be fully completed. The healthcare provider may choose to omit certain information for 
some or all patients, e.g. employment. Relevant descriptors of an illness may not be 
recorded, e.g. staging of cancer. Similar limitations are documented in other research 
projects. For example, one study, by Abidi et al.156 described an underreporting of alcohol 
use disorders from GPs when using an EMR. It was theorized that it could be due to barriers 
related to alcohol screening but also avoidance due to the stigma around alcohol abuse. 
This stigma is seen in many aspects of mental health conditions and could be affecting the 
documentation on EMRs. Statistics Canada157 reported that only 57% of Canadians 
consulted their family doctor or general practitioner for mental health care when seeking 
help. The other fraction was divided among social workers, nurses, psychiatrists, 
psychologists, and others. If the patient sought counseling on their mental health from a 
healthcare professional other than a practitioner participating with CPCSSN, it would not 
appear in the database. In terms of prescriptions, the reason for use is not described 
rendering it challenging to determine if the medication is for traditional or off-label use. 
For example, Zaini et al.160 discussed the use of antidepressant medications for other 
somatic complaints, other than depressed mood, such as hot flashes, sexual dysfunction, 
pruritus, nausea, cachexia, fatigue, nicotine dependence, and others. Unfortunately, with 
the limitations presented by the CPCSSN database, these prescriptions are not screened for 
and their use are assumed to be due to mental illness. Due to limitations of the dataset, this 
study was unable to analyze time from diagnosis of cancer to mental illness. A meta-
analysis by Krebber et al.152 was able to look at point prevalence of depression in patients 
throughout the first year after a diagnosis of cancer. Highest rates were seen acutely after 
diagnosis which then decreased. Burgess et al.161 conducted a similar study, including the 
point prevalence of anxiety. They too, found that 33% of oncology patients experienced 
depression and/or anxiety at time of diagnosis. This decreased to 24% at 3 months post 
diagnosis and 15% at 1 year after treatment. 
This study focused on the presence of any mental health condition; however, the 
majority of literature focuses on the presence of depression. One study, The increasing 
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burden of depression162, looked at the prevalence of and burden caused by depression. It 
used disability adjusted life-years (DALY), a sum of life-years lost due to premature death 
and years of life with disability, taking severity into consideration. This study, conducted 
in 2011, considered depression among the leading causes of worldwide disease and burden 
and predicted it to become the major health burden worldwide by 2030. Thus, it becomes 
crucial to recognize risk factors and the presence of depression in patients.  Due to the 
increased frequency of depression and the often large negative effect on QOL, most 
research on mental health in cancer patients has this focus. There are, however, many other 
mental health conditions that may form in the year following a diagnosis of cancer. Based 
on current literature, there needs to be a wider focus to include these in future research 
endeavors. As mentioned earlier, poor QOL can negatively impact mental health. 
Unfortunately, it was not possible to control for QOL in this study due to the nature of the 
CPCSSN data.   
4.3 Summary of Findings 
 This study aims to evaluate the relationship between a first diagnosis of cancer and 
the development of subsequent mental health disorders. Results from this study show that 
a diagnosis of cancer doubles an individual’s risk of developing a mental health disorder 
indicator, i.e. were diagnosed with a mental health disorder, prescribed psychoactive drugs, 
and/or given a referral for a mental health specialist. There was not found to be a significant 
difference between the type of cancer diagnosed and the presence of a mental health 
condition indicator. There was, however, a significant difference found between the 
presence of cancer and the type of mental disorder diagnosis as well as the type of 
psychoactive drug prescribed. Anxiety, depression, mood, and stress-related disorders 
were most commonly diagnoses. Anxiolytics were the most frequently prescribed 
psychoactive drug overall, however, antidepressants were most common in the exposed 
cohort. 
4.4 Implication of Study 
 
There is currently little literature available that discusses the link between cancer 
and mental illness outside of the diagnosis of depression. While this project broadened that 
focus to include other mental health disorder diagnoses, it was limited by the available 
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data. Researchers should continue to explore the relationship between cancer diagnoses 
and mental health disorders to promote change in practice.   
Findings from this study should oblige clinical healthcare practitioners to promote 
screening for mental illness in their oncology patients as routine care. Findings from this 
study should encourage policy change to incorporate counsellors, psychologists, and/or 
social workers on the team for management of oncology patients. Collaboration of the 
oncology patients’ primary healthcare providers and providers specializing in mental 
health care should be increased to address the higher rates of mental illness and unmet 
needs of this population.  
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